Facing the pandemic caused by SARS-CoV-2, ACROBiosystems has been keeping a close eye on the development of the epidemic situation and accelerating the development of SARS-COV-2 antigen proteins, antibodies, kits and other related products to facilitate the development of serologic tests, therapeutic antibodies and vaccines.
ACROBiosystems are ISO 9001 certified and use a proprietary HEK293 expression platform to generate human proteins with authentic folding and post-translational modifications. Notably they offer recombinant proteins un-labelled, tagged or labelled with their unique labelling technologies, yielding high binding activity and minimal batch to batch variation.